Oncology Based Molecular Diagnostics Market Growth, Size, Trends Analysis- By Type, By Product, By Technology - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Oncology Based Molecular Diagnostics Market Introduction and Overview

According to SPER market research, 'Global Oncology Based Molecular Diagnostics Market Size- By Component, By Industry - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Oncology Based Molecular Diagnostics Market is predicted to reach 12.47 billion by 2034 with a CAGR 12.36%.

Oncology-based molecular diagnostics is a specialized area of medical testing that utilizes molecular biology techniques to identify genetic, epigenetic, and proteomic changes linked to cancer. These tests are instrumental in detecting specific mutations, gene expression patterns, or biomarkers within cancer cells, which are essential for accurate diagnosis, prognosis, and selecting appropriate treatments.

Restraints: The oncology-based molecular diagnostics market encounters several significant challenges. A primary obstacle is the high cost of advanced diagnostic technologies, which can restrict access, especially in low- and middle-income countries. The complex nature of cancer biology and tumor heterogeneity also makes it challenging to create molecular tests that are universally effective.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Type, By Product, By Technology

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Abbott, Bayer AG, BD, Cepheid, Agilent Technologies, Inc., Danaher, Hologic, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens.

Global Oncology Based Molecular Diagnostics Market Segmentation:

By Type: Based on the Type, Global Oncology Based Molecular Diagnostics Market is segmented as; Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Other Cancer.

By Product: Based on the Product, Global Oncology Based Molecular Diagnostics Market is segmented as; Instruments, Reagents, Others

By Technology: Based on the Technology, Global Oncology Based Molecular Diagnostics Market is segmented as; PCR, In Situ Hybridization, INAAT, Chips and Microarrays, Mass Spectrometry, Sequencing, TMA, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Product Code: BIOT2502

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Oncology Based Molecular Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oncology Based Molecular Diagnostics Market

7. Global Oncology Based Molecular Diagnostics Market, By Type, (USD Million) 2021-2034

7.1. Breast Cancer
7.2. Prostate Cancer
7.3. Colorectal Cancer
7.4. Cervical Cancer
7.5. Liver Cancer
7.6. Lung Cancer
7.7. Blood Cancer
7.8. Kidney Cancer
7.9. Other Cancer

8. Global Oncology Based Molecular Diagnostics Market, By Product, (USD Million) 2021-2034

8.1. Instruments
8.2. Reagents
8.3. Others

9. Global Oncology Based Molecular Diagnostics Market, By Technology, (USD Million) 2021-2034

9.1. PCR
9.2. In Situ Hybridization
9.3. INAAT
9.4. Chips and Microarrays
9.5. Mass Spectrometry
9.6. Sequencing
9.7. TMA
9.8. Others

10. Global Oncology Based Molecular Diagnostics Market, (USD Million) 2021-2034

10.1. Global Oncology Based Molecular Diagnostics Market Size and Market Share

11. Global Oncology Based Molecular Diagnostics Market, By Region, 2021-2034 (USD Million)

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Abbott
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Bayer AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. BD
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Cepheid
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Agilent Technologies, Inc.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Danaher
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Hologic, Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Qiagen
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. F. Hoffmann-La Roche Ltd.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Siemens
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others